 |
 |
Product ID |
Structure |
Product Name |
Purity |
Price(s) |
Delete |
Y1335366 |
 |
(2-bromopyrimidin-5-yl)methanol |
95%
|
$405/10mg |
 |
Y3211339 |
 |
[2-(6-fluoro-1H-indol-3-yl)ethyl](methyl)amine |
95%
|
|
 |
Y3308254 |
 |
1,8-BIS(CHLORODIMETHYLSILYL)OCTANE |
97%
|
$55/250mg |
 |
Y1265356 |
 |
2-((5-Bromo-4-methylpyridin-2-yl)amino)ethanol |
95%
|
$100/250mg, $190/1g |
 |
Y3122654 |
 |
2-[(2-aminobenzoyl)amino]benzoic acid |
95%
|
$180/50mg, $210/100mg, $275/250mg, $505/500mg, $675/1g |
 |
Y3258735 |
 |
2-[benzyl(carboxymethyl)amino]acetic acid hydrochloride |
95%
|
$85/250mg, $90/500mg, $95/1g |
 |
Y3110258 |
 |
3-(3-bromophenyl)-5-(pyrrolidin-2-yl)-1,2,4-oxadiazole |
90%
|
$265/50mg, $385/100mg, $530/250mg, $830/500mg, $1065/1g |
 |
Y0997959 |
 |
3-chloro-6-methoxy-1H-pyrrolo[3,2-c]pyridine |
95%
|
$2700/5g |
 |
Y3209438 |
 |
4'-METHOXY-BIPHENYL-2-METHANAMINE |
97%
|
$205/500mg, $315/1g, $915/5g |
 |
Y3241156 |
 |
4-(azetidin-3-yl)-2-bromo-1,3-thiazole, trifluoroacetic acid |
95%
|
$500/50mg, $745/100mg, $1055/250mg, $1660/500mg, $2125/1g, $4160/2.5g, $6155/5g |
 |
Y1472856 |
 |
4-Bromo-isothiazole-5-carboxylic acid ethyl ester |
95%
|
$455/50mg, $555/100mg, $780/250mg, $1115/500mg, $1785/1g, $6715/5g |
 |
Y1006241 |
 |
cis-3-methoxycyclohexanamine;hydrochloride |
97%
|
$165/100mg, $255/250MG, $410/500MG, $620/1G, $1860/5G, $3105/10G |
 |
D580680 |
 |
Ethoxyamine hydrochloride |
97%
|
$250/500g |
 |
Y3265140 |
 |
ETHYLBUTYLNITROSAMINE |
95%
|
$355/50mg, $510/100mg, $720/250mg, $1130/500mg, $1450/1g |
 |
Y3270810 |
 |
Morpholine, 4-[5-(phenylmethylene)-1-cyclopenten-1-yl]- |
95%
|
$125/50mg, $160/100mg, $175/250mg, $300/500mg, $430/1g |
 |
Y3216961 |
 |
N'-(3-bromo-5-methylbenzylidene)-4-methylbenzenesulfonohydrazide |
95%
|
$420/5g, $695/10g |
 |
Y3235807 |
 |
rac-(1R,2R)-4,4-difluorocyclopentane-1,2-diol, trans |
95%
|
|
 |
Y3192613 |
 |
sodium5-(pyridin-2-yl)-4H-1,2,4-triazole-3-carboxylate |
95%
|
$550/50mg, $810/100mg, $1160/250mg, $1820/500mg, $2335/1g |
 |
Y3317732 |
 |
TIN ARSENIDE |
99.999%
|
|
 |
|
|
|
 |
 |
 |